Compugen Presents Initial Clinical Data from Ongoing Phase 1 Trial of COM701 in Patients with Advanced Solid Tumors at SITC 2019
Compugen Ltd. - Ordinary Shares (CGEN)
Last compugen ltd. - ordinary shares earnings: 2/20 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
cgen.com/investors/overview
Company Research
Source: PR Newswire
HOLON, Israel, Nov. 5, 2019 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today disclosed preliminary results from its ongoing Phase 1 dose escalation study of COM701, a first-in-class anti-PVRIG antibody, in patients with advanced solid tumors. COM701 was well-tolerated with no dose-limiting toxicities observed. Furthermore, COM701 demonstrated initial signals of anti-tumor activity in the heavily pretreated patient population enrolled on the study. The clinical data will be presented in a poster titled "Phase 1 Study of the Safety, Tolerability and Preliminary Anti-Tumor Activity of COM701 Monotherapy in Patients with Advanced Solid Tumors" at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019) on Friday, November 8, 2019."We are encouraged by the emerging safety profile and initial signals of anti-tumor activity of COM701. While the primary objective of this portion
Show less
Read more
Impact Snapshot
Event Time:
CGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGEN alerts
High impacting Compugen Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
CGEN
News
- Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024PR Newswire
- Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024PR Newswire
- Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503PR Newswire
- Compugen to Participate in Two Upcoming Investor ConferencesPR Newswire
- Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 31% Discount? [Yahoo! Finance]Yahoo! Finance